MELK
Top inhibitors
| Drug | Inhibition % | Gini |
|---|---|---|
| Nintedanib | 99.4 | 0.61 |
| Midostaurin | 94.9 | 0.50 |
| Sunitinib | 87.8 | 0.52 |
| Defactinib | 81.4 | 0.45 |
| Neratinib | 78.2 | 0.60 |
| Alectinib | 70.3 | 0.65 |
| Selpercatinib | 60.4 | 0.64 |
| Brigatinib | 51.4 | 0.51 |
| Tepotinib | 50.4 | 0.73 |
| Palbociclib | 46.6 | 0.67 |
| Gilteritinib | 44.6 | 0.51 |
| Dabrafenib | 42.7 | 0.63 |
| Fedratinib | 42.6 | 0.58 |
| Ponatinib | 40.0 | 0.53 |
| Gefitinib | 31.0 | 0.65 |
Known variants
Cancer associations
| Mutation | Cancer type | Organ | Source |
|---|---|---|---|
T460M | carcinoma_ovary | Ovary | https://doi.org/10.1093/nar/gkaa945 |
T460M | carcinoma_kidney | Kidney | https://doi.org/10.1093/nar/gkaa945 |
T460M | COREAD | Large Intestine | https://doi.org/10.1093/nar/gkaa945 |